Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885.
The company is slated to report its second-quarter FY24 earnings on August 8.
The analyst highlighted that Eli Lilly's GAAP and non-GAAP financial results for 2Q24 will include acquired IPR&D charges of ~$154 million on a pre-tax basis, representing a charge of ~$0.14 to both GAAP and non-GAAP earnings per share.
The following are some of the points the analyst lists that are important for the company's growth in the coming days.
The analyst expects U.S. approval for Lebrikizumab to treat atopic dermatitis in 2H24E.
Also Read: Eli Lilly Announces CFO Change
The analyst also expects Morphic acquisition to close in 3Q24. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of IBD.
By the end of 2024, LLY expects to have results of SURMOUNT-5 which is its H2H study of tirzepatide vs. high-dose semaglutide in participants with obesity, said the analyst.
The analyst sees the first set of Phase 3 results on orforglipron in T2D/obesity in 2025, from Phase 3 ACHIEVE T2D program.
LLY submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. FDA with regulatory action anticipated as early as the end of this year, said the analyst.
Key competitive readouts that the analyst looks forward to include, Novo Nordisk A/S's (NYSE:NVO) semaglutide in MASH, Akero Therapeutics Inc's (NASDAQ:AKRO) efruxifermin (FGF21 analog) in MASH and Novo Nordisk's CagriSema Phase 3 program for obesity.
Read Next:
- Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Price Action: LLY shares are trading higher by 0.475 at $952.82 at last check Monday.
Photo by rafapress on Shutterstock
坎託·菲茨傑拉德分析師路易絲·陳重申了對禮來公司（紐約證券交易所代碼：LLY）股票的增持評級，並將目標股價維持在885美元。
該公司定於8月8日公佈其24財年第二季度收益。
該分析師強調，禮來公司24年第二季度的GAAP和非GAAP財務業績將包括收購的約1.54億美元的稅前IPR&D費用，相當於對GAAP和非GAAP每股收益收取約0.14美元的費用。
以下是分析師列出的一些觀點，這些觀點對公司未來幾天的增長很重要。
該分析師預計，美國批准雷博珠單抗用於治療 2H24E 中的特應性皮炎。
另請閱讀：禮來公司宣佈首席財務官變動
該分析師還預計，對Morphic的收購將在24年第三季度完成。Morphic的主要項目是α4β7整合素的選擇性口服小分子抑制劑，用於治療IBD。
該分析師表示，到2024年底，LLY預計將得出Surmount-5的結果，這是其對肥胖參與者中替塞帕肽與高劑量索瑪魯肽的H2H研究。
該分析師認爲，2025年Orforglipron在T2D/肥胖中的第一組第三階段結果來自第三階段ACHIEVE T2D計劃。
該分析師表示，LLY向美國食品藥品管理局提交了用於治療中度至重度OSA和肥胖症的替塞帕肽，預計最早將在今年年底採取監管行動。
分析師希望包括的主要競爭數據，包括MASH中的諾和諾德公司（紐約證券交易所代碼：NVO）的索瑪魯肽、MASH中的Akero Therapeutics Inc（納斯達克股票代碼：AKRO）efruxifermin（FGF21 類似物）以及諾和諾德的CagriSEMA第三階段肥胖計劃。
繼續閱讀：
- 分析師：儘管投資者關注肥胖問題，但禮來公司的32億美元形態交易 “至關重要”，具有 “戰略價值”
價格走勢：週一最後一次檢查時，LLY股價上漲0.475美元，至952.82美元。
照片由 rafapress 在 Shutterstock 上拍攝
